
--- Page 1 ---
510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION
DECISION SUMMARY
ASSAY ONLY TEMPLATE
A. 510(k) Number:
k163590
B. Purpose for Submission:
New device
C. Measurand:
Benzodiazepines
D. Type of Test:
Qualitative screening test: enzyme immunoassay (EIA)
Quantitative confirmatory test: LC/MS/MS
E. Applicant:
Psychemedics Corporation
F. Proprietary and Established Names:
Psychemedics Microplate EIA for Benzodiazepines in Hair
G. Regulatory Information:
Product Code Classification Regulation Section Panel
JXM Class II 21 CFR 862.3170 Toxicology (91)
H. Intended Use:
1. Intended use(s):
Refer to Indications for Use below.
2. Indication(s) for use:
The Psychemedics Microplate EIA For Benzodiazepines in Hair is an in vitro diagnostic
device for the qualitative detection of benzodiazepines in hair. The assay is intended for
1

[Table 1 on page 1]
	Product Code			Classification			Regulation Section			Panel	
JXM			Class II			21 CFR 862.3170			Toxicology (91)		

--- Page 2 ---
use in workplace settings for the qualitative analysis of human head and body hair. The
assay uses a cutoff calibrator of 1 ng oxazepam/10 mg hair.
Psychemedics plans to perform this test at one site. Psychemedics has not performed an
evaluation of reproducibility at different laboratories.
The Psychemedics Microplate EIA For Benzodiazepines in Hair provides only a
preliminary analytical test result. A more specific alternate chemical method must be
used to obtain a confirmed analytical result. Liquid Chromatography/Mass
spectrometry/Mass spectrometry (LC/MS/MS) using deuterated internal standards in
multiple reaction monitoring (MRM) mode is the confirmatory method used by
Psychemedics Corporation. This confirmatory method uses a cutoff of 0.2 ng of the
identified benzodiazepine/10 mg hair.
3. Special conditions for use statement(s):
This assay is for over the counter use.
The Psychemedics Microplate EIA for Benzodiazepines in Hair combines a screening
method (immunoassay) with a confirmation method (LC/MS/MS) in one test system.
4. Special instrument requirements:
The device is for use with a microplate reader capable of measuring at 450 and 630 nm.
Plate washing also requires an instrument specifically designed to effectively and
reproducibly wash all wells uniformly.
For confirmation testing, Psychemedics uses a AB Sciex API 3200 LC/MS/MS (Serial
numbers AA24661109 and AA28841310), in multiple reaction monitoring (MRM) mode,
linked to two Shimazu LC-20AD Micro pumps and a Leap Technologies PAL
autosampler, along with deuterated internal standards.
I. Device Description:
The screening assay consists of:
· BSA-oxazepam coated Microplate
· Cutoff Calibrator (.8 ng oxazepam/37 uL) added to 8 mg hair
· Controls (minus 50% of cutoff, and plus 100% of cutoff)
· Primary antibody against oxazepam and other benzodiazepines
· HRP-labeled secondary antibody directed against the primary antibody species
· Substrate TMB (tetramethylbenzidine)
· Acidic stop solution (2 N HCl)
· Hair sample collection kit
The confirmation assay consists of a Perkin Elmer Sciex API 3200 LC/MS/MS (Serial
2

--- Page 3 ---
numbers AA24661109 and AA28841310) linked to two Shimazu LC-20AD Micro pumps
and a Leap Technologies PAL autosampler, an internal standard (0.2 ng oxazepam/10 mg
hair), Signal peak identification and integration are performed with AB Sciex MultiQuant
Software, version 1.5.1 and 1.6.2, using the SignalFinder Integration Algorithm that is a
feature of the MultiQuant Software.
J. Substantial Equivalence Information:
1. Predicate device name(s):
Orasure Technologies Benzodiazepines Intercept Micro-plate EIA
2. Predicate 510(k) number(s):
k013882
3. Comparison with predicate:
Similarities
Device: Predicate:
Psychemedics Microplate k013882 Orasure
Item
EIA for Benzodiazepines in Benzodiazepine Intercept
Hair Micro-plate EIA
Qualitative detection of
Intended Use Same
benzodiazepines
Same Enzyme Immunoassay read
Methodology
at 450 nm
Calibrator Drug Same Oxazepam
Differences
Device: Predicate:
Psychemedics Microplate k013882 Orasure
Item
EIA for Benzodiazepines in Benzodiazepine Intercept
Hair Micro-plate EIA
Matrix Hair Oral Fluid
Confirmation Method LC/MS/MS GC/MS/MS
Cutoff 1 ng / 10 mg hair 1 ng / mL oral fluid
Intended to be used in house Intended to be marketed to
Intended User
at Psychemedics only individual laboratories
Required; performed in-
Extraction Step Not required
house
K. Standard/Guidance Document Referenced (if applicable):
None referenced
3

[Table 1 on page 3]
Similarities						
Item		Device:			Predicate:	
		Psychemedics Microplate			k013882 Orasure	
		EIA for Benzodiazepines in			Benzodiazepine Intercept	
		Hair			Micro-plate EIA	
Intended Use	Same			Qualitative detection of
benzodiazepines		
Methodology	Same			Enzyme Immunoassay read
at 450 nm		
Calibrator Drug	Same			Oxazepam		

[Table 2 on page 3]
Differences						
Item		Device:			Predicate:	
		Psychemedics Microplate			k013882 Orasure	
		EIA for Benzodiazepines in			Benzodiazepine Intercept	
		Hair			Micro-plate EIA	
Matrix	Hair			Oral Fluid		
Confirmation Method	LC/MS/MS			GC/MS/MS		
Cutoff	1 ng / 10 mg hair			1 ng / mL oral fluid		
Intended User	Intended to be used in house
at Psychemedics only			Intended to be marketed to
individual laboratories		
Extraction Step	Required; performed in-
house			Not required		

--- Page 4 ---
L. Test Principle:
The Psychemedics Microplate EIA For Benzodiazepines in Hair consists of (1) a screening
immunoassay and (2) a confirmation test by LC-MS/MS.
The screening immunoassay consists of two parts; a pre-analytical hair treatment procedure
(to remove benzodiazepines from solid hair matrix to a measurable liquid matrix), and the
qualitative assay. The qualitative assay is an Enzyme-Linked ImmunoSorbent Assay
(ELISA) based upon the competitive binding of benzodiazepines in the sample and solid-
phase oxazepam in the microplate wells to the assay detection antibody. Sample is added to
the microplate well, followed by primary antibody (monoclonal mouse anti-oxazepam), and
then (after washing the plate) goat anti-mouse-horseradish peroxidase conjugate is added.
Enzyme substrate is then added and the plate is read on a microplate reader at 450 nm.
Confirmatory testing:
Confirmation testing of samples is performed on a 6-12 mg aliquot of the original hair
specimen. The hair is washed with isopropanol, followed by phosphate buffer. After
washing, samples are then spiked with deuterated benzodiazepines (Alprazolam-D5,
Lorazepam-D4, Diazepam-D5, Nordiazepam-D5, Oxazepam-D5, and Temazepam-D5) to a
concentration of 1.0 ng/10 mg hair, processed by solid phase extraction and analyzed using
the Perkin Elmer Sciex API 3200 LC/MS/MS operating in the Positive Multiple Reaction
Mode. To account for variability in drug recovery during solid phase extraction the recovered
concentration of the deuterated internal standards in each sample is used to normalize the
data for that sample.
M. Performance Characteristics:
1. Analytical performance:
a. Precision/Reproducibility:
Precision of the immunoassay screening method
Hair samples previously tested and shown to be negative for benzodiazepines
were spiked with oxazepam at the following concentrations: 0, 0.25, 0.5, 0.75,
1.0, 1.25, 1.5, 1.75, and 2 ng/10 mg hair (negative, ±75%, ±50%, ±25%, cutoff,
and +100% of the cutoff). Intra-Assay Precision was demonstrated by measuring
these nine concentrations of oxazepam in hair samples in replicates of 15 within
a single run. Results are summarized below.
4

--- Page 5 ---
Concentration relative
to cutoff (1 ng/10 mg No. Samples Negative / Positive
hair)
Negative 15 15/0
25% 15 15/0
50% 15 15/0
75% 15 15/0
Cutoff 15 7/8
125% 15 0/15
150% 15 0/15
175% 15 0/15
200% 15 0/15
Hair samples previously tested and shown to be negative for benzodiazepines
were spiked with oxazepam at the following concentrations: 0, 0.25, 0.5, 0.75,
1.0, 1.25, 1.5, 1.75, and 2 ng/10 mg hair (negative, ±75%, ±50%, ±25%, cutoff,
and +100% of the cutoff). Inter-Assay Precision of the assay was evaluated by
measuring these nine concentrations of oxazepam in hair samples over the course
of five days, in replicates of 15 per day. Results are summarized below.
Concentration relative
to cutoff (1 ng/10 mg No. Samples Positive / Negative
hair)
Negative 75 75/0
25% 75 75/0
50% 75 75/0
75% 75 75/0
Cutoff 75 43/32
125% 75 0/75
150% 75 0/75
175% 75 0/75
200% 75 0/75
Precision of the LC-MS/MS method
Intermediate precision around the LC/MS/MS cutoff was conducted using drug
negative hair samples spiked with 0.05, 0.1, 0.15, 0.2, 0.25, or 0.3 ng/10 mg hair.
Samples were prepared in replicates of 5 per each concentration, and run over 5
days for 25 determinations per drug. Results for the six benzodiazepines
measured by the LC-MS/MS assay are summarized below.
5

[Table 1 on page 5]
Concentration relative
to cutoff (1 ng/10 mg
hair)	No. Samples	Negative / Positive
Negative	15	15/0
25%	15	15/0
50%	15	15/0
75%	15	15/0
Cutoff	15	7/8
125%	15	0/15
150%	15	0/15
175%	15	0/15
200%	15	0/15

[Table 2 on page 5]
Concentration relative
to cutoff (1 ng/10 mg
hair)	No. Samples	Positive / Negative
Negative	75	75/0
25%	75	75/0
50%	75	75/0
75%	75	75/0
Cutoff	75	43/32
125%	75	0/75
150%	75	0/75
175%	75	0/75
200%	75	0/75

--- Page 6 ---
ALPRAZOLAM (ng/10 mg hair)
Concentration 0.05 0.10 0.15 0.20 0.25 0.30
Average 0.0510 0.1031 0.1513 0.2088 0.2551 0.3128
S.D. 0.0049 0.0093 0.0100 0.0109 0.0111 0.0188
% CV 9.66 8.99 6.59 5.23 4.37 6.00
Percent of 102.1 103.1 100.9 104.4 102.0 104.3
Target
LORAZEPAM (ng/10mg hair)
Concentration 0.05 0.10 0.15 0.20 0.25 0.30
Average 0.05088 0.10128 0.1502 0.19632 0.24548 0.29756
S.D. 0.0046 0.0060 0.0104 0.0144 0.0123 0.0164
% CV 9.03 5.93 6.92 7.34 5.02 5.52
Percent of Target 101.8 101.3 100.1 98.2 98.2 99.2
DIAZEPAM (ng/10 mg hair)
Concentration 0.05 0.10 0.15 0.20 0.25 0.3
Average 0.0498 0.1035 0.1587 0.2095 0.2661 0.3179
S.D. 0.0047 0.0062 0.0113 0.0143 0.0131 0.0190
% CV 9.51 6.01 7.12 6.84 4.92 5.99
Percent of 99.7 103.5 105.8 104.8 106.4 106.0
Target
NORDIAZEPAM (ng/10mg hair)
Concentration 0.05 0.10 0.15 0.20 0.25 0.30
Average 0.0490 0.0990 0.1502 0.1960 0.2478 0.3044
S.D. 0.0043 0.0068 0.0103 0.0097 0.0149 0.0171
% CV 8.72 6.83 6.86 4.93 6.01 5.62
Percent of Target 98.0 99.0 100.1 98.0 99.1 101.5
OXAZEPAM (ng/10mg hair)
Concentration 0.05 0.10 0.15 0.20 0.25 0.30
Average 0.0497 0.1016 0.1554 0.1991 0.2576 0.3102
S.D. 0.0042 0.0082 0.0120 0.0105 0.0130 0.0115
% CV 8.50 8.10 7.71 5.29 5.06 3.72
Percent of 99.4 101.6 103.6 99.5 103.1 103.4
Target
6

[Table 1 on page 6]
	ALPRAZOLAM (ng/10 mg hair)					
Concentration	0.05	0.10	0.15	0.20	0.25	0.30
Average	0.0510	0.1031	0.1513	0.2088	0.2551	0.3128
S.D.	0.0049	0.0093	0.0100	0.0109	0.0111	0.0188
% CV	9.66	8.99	6.59	5.23	4.37	6.00
Percent of
Target	102.1	103.1	100.9	104.4	102.0	104.3

[Table 2 on page 6]
	LORAZEPAM (ng/10mg hair)					
Concentration	0.05	0.10	0.15	0.20	0.25	0.30
Average	0.05088	0.10128	0.1502	0.19632	0.24548	0.29756
S.D.	0.0046	0.0060	0.0104	0.0144	0.0123	0.0164
% CV	9.03	5.93	6.92	7.34	5.02	5.52
Percent of Target	101.8	101.3	100.1	98.2	98.2	99.2

[Table 3 on page 6]
	DIAZEPAM (ng/10 mg hair)					
Concentration	0.05	0.10	0.15	0.20	0.25	0.3
Average	0.0498	0.1035	0.1587	0.2095	0.2661	0.3179
S.D.	0.0047	0.0062	0.0113	0.0143	0.0131	0.0190
% CV	9.51	6.01	7.12	6.84	4.92	5.99
Percent of
Target	99.7	103.5	105.8	104.8	106.4	106.0

[Table 4 on page 6]
	NORDIAZEPAM (ng/10mg hair)					
Concentration	0.05	0.10	0.15	0.20	0.25	0.30
Average	0.0490	0.0990	0.1502	0.1960	0.2478	0.3044
S.D.	0.0043	0.0068	0.0103	0.0097	0.0149	0.0171
% CV	8.72	6.83	6.86	4.93	6.01	5.62
Percent of Target	98.0	99.0	100.1	98.0	99.1	101.5

[Table 5 on page 6]
	OXAZEPAM (ng/10mg hair)					
Concentration	0.05	0.10	0.15	0.20	0.25	0.30
Average	0.0497	0.1016	0.1554	0.1991	0.2576	0.3102
S.D.	0.0042	0.0082	0.0120	0.0105	0.0130	0.0115
% CV	8.50	8.10	7.71	5.29	5.06	3.72
Percent of
Target	99.4	101.6	103.6	99.5	103.1	103.4

--- Page 7 ---
TEMAZEPAM (ng/10ng hair)
Concentration 0.05 0.10 0.15 0.20 0.25 0.30
Average 0.0504 0.0978 0.1495 0.1993 0.2492 0.2996
S.D. 0.0029 0.0060 0.0070 0.0065 0.0086 0.0070
% CV 5.67 6.17 4.65 3.27 3.45 2.32
Percent of 100.7 97.8 99.7 99.7 99.7 99.9
Target
Within run precision throughout the LC/MS/MS range was conducted using drug
negative hair samples spiked with 0.05, 0.1, 0.15, 0.2, 1.0, 10.0, 15.0, or 20.0
ng/10 mg hair. Samples were prepared in replicates of 5, per each concentration,
and concentrations were determined in one run. Results for the six
benzodiazepines measured by the LC-MS/MS assay are summarized below.
Target Concentration (ng/10 mg hair)
0.05 0.10 0.15 0.20 1.0 10 15 20
Alprazolam 0.056 0.100 0.158 0.234 0.947 10.395 15.898 20.496
concentration 0.051 0.092 0.148 0.217 0.953 10.279 15.885 19.164
0.054 0.093 0.162 0.222 0.903 10.430 15.934 20.332
0.045 0.095 0.161 0.200 0.944 10.670 14.732 20.049
0.053 0.090 0.164 0.198 0.947 10.196 15.577 20.197
Average 0.0518 0.094 0.1586 0.2142 0.9388 10.394 15.605 20.0476
S.D. 0.004 0.004 0.006 0.015 0.020 0.180 0.509 0.521
% CV 8.12 4.05 3.98 7.10 2.16 1.73 3.26 2.60
% of Target 103.6 94.0 105.7 107.1 93.9 103.9 104.0 100.2
Lorazepam 0.052 0.085 0.154 0.22 0.906 10.191 15.072 19.987
concentration 0.044 0.092 0.147 0.21 0.923 10.165 14.604 18.966
0.05 0.092 0.148 0.204 0.895 10.262 14.41 19.077
0.05 0.102 0.137 0.2 0.92 10.429 15.425 19.461
0.054 0.1 0.163 0.218 0.905 10.927 14.393 18.933
Average 0.05 0.0942 0.1498 0.2104 0.9098 10.394 14.780 19.2848
S.D. 0.004 0.007 0.010 0.009 0.012 0.315 0.452 0.445
% CV 7.48 7.29 6.39 4.11 1.27 3.03 3.06 2.31
% of Target 100.0 94.2 99.9 105.2 91.0 103.9 98.5 96.4
7

[Table 1 on page 7]
	TEMAZEPAM (ng/10ng hair)					
Concentration	0.05	0.10	0.15	0.20	0.25	0.30
Average	0.0504	0.0978	0.1495	0.1993	0.2492	0.2996
S.D.	0.0029	0.0060	0.0070	0.0065	0.0086	0.0070
% CV	5.67	6.17	4.65	3.27	3.45	2.32
Percent of
Target	100.7	97.8	99.7	99.7	99.7	99.9

[Table 2 on page 7]
	Target Concentration (ng/10 mg hair)							
	0.05	0.10	0.15	0.20	1.0	10	15	20
Alprazolam
concentration	0.056
0.051
0.054
0.045
0.053	0.100
0.092
0.093
0.095
0.090	0.158
0.148
0.162
0.161
0.164	0.234
0.217
0.222
0.200
0.198	0.947
0.953
0.903
0.944
0.947	10.395
10.279
10.430
10.670
10.196	15.898
15.885
15.934
14.732
15.577	20.496
19.164
20.332
20.049
20.197
Average
S.D.
% CV
% of Target	0.0518	0.094	0.1586	0.2142	0.9388	10.394	15.605	20.0476
	0.004	0.004	0.006	0.015	0.020	0.180	0.509	0.521
	8.12	4.05	3.98	7.10	2.16	1.73	3.26	2.60
	103.6	94.0	105.7	107.1	93.9	103.9	104.0	100.2
								
Lorazepam
concentration	0.052
0.044
0.05
0.05
0.054	0.085
0.092
0.092
0.102
0.1	0.154
0.147
0.148
0.137
0.163	0.22
0.21
0.204
0.2
0.218	0.906
0.923
0.895
0.92
0.905	10.191
10.165
10.262
10.429
10.927	15.072
14.604
14.41
15.425
14.393	19.987
18.966
19.077
19.461
18.933
Average
S.D.
% CV
% of Target	0.05	0.0942	0.1498	0.2104	0.9098	10.394	14.780	19.2848
	0.004	0.007	0.010	0.009	0.012	0.315	0.452	0.445
	7.48	7.29	6.39	4.11	1.27	3.03	3.06	2.31
	100.0	94.2	99.9	105.2	91.0	103.9	98.5	96.4

--- Page 8 ---
Diazepam 0.053 0.088 0.15 0.211 0.928 10.417 14.39 18.679
concentration 0.054 0.092 0.151 0.201 0.945 10.354 14.444 18.06
0.044 0.084 0.163 0.203 0.96 10.561 14.943 19.458
0.049 0.085 0.143 0.196 0.949 10.03 14.692 19.613
0.054 0.094 0.167 0.209 0.936 10.439 14.661 19.133
Average 0.0508 0.0886 0.1548 0.204 0.9436 10.360 14.626 18.9886
S.D. 0.004 0.004 0.010 0.006 0.012 0.199 0.221 0.630
% CV 8.51 4.89 6.40 2.98 1.30 1.92 1.51 3.32
% of Target 101.6 88.6 103.2 102.0 94.4 103.6 97.5 94.9
Target Concentration (ng/10 mg hair)
0.05 0.10 0.15 0.20 1.0 10 15 20
0.049 0.086 0.151 0.201 0.904 10.659 14.942 19.881
Nordiazepam
concentration 0.048 0.088 0.155 0.2 0.947 10.654 14.836 19.869
0.056 0.092 0.14 0.201 0.937 10.278 14.917 20.328
0.047 0.093 0.161 0.213 0.933 10.738 14.94 19.692
0.044 0.095 0.163 0.208 0.902 10.132 14.717 19.635
Average 0.0488 0.0908 0.154 0.2046 0.9246 10.492 14.870 19.881
S.D. 0.004 0.004 0.009 0.006 0.020 0.269 0.096 0.272
% CV 9.10 4.08 5.95 2.78 2.20 2.57 0.65 1.37
% of Target 97.6 90.8 102.7 102.3 92.5 104.9 99.1 99.4
Oxazepam 0.058 0.101 0.168 0.21 0.926 9.841 15.053 19.451
concentration 0.05 0.093 0.168 0.211 0.93 10.277 14.791 19.701
0.049 0.099 0.161 0.198 0.903 10.146 14.561 19.889
0.048 0.091 0.158 0.2 0.905 10.394 15.271 19.595
0.055 0.093 0.162 0.198 0.878 10.417 15.164 19.593
Average 0.052 0.0954 0.1634 0.2034 0.9084 10.215 14.968 19.6458
S.D. 0.004 0.004 0.004 0.007 0.021 0.235 0.289 0.162
% CV 8.27 4.54 2.72 3.22 2.30 2.30 1.93 0.83
% of Target 104.0 95.4 108.9 101.7 90.8 102.2 99.8 98.2
8

[Table 1 on page 8]
Diazepam
concentration	0.053
0.054
0.044
0.049
0.054	0.088
0.092
0.084
0.085
0.094	0.15
0.151
0.163
0.143
0.167	0.211
0.201
0.203
0.196
0.209	0.928
0.945
0.96
0.949
0.936	10.417
10.354
10.561
10.03
10.439	14.39
14.444
14.943
14.692
14.661	18.679
18.06
19.458
19.613
19.133
Average
S.D.
% CV
% of Target	0.0508	0.0886	0.1548	0.204	0.9436	10.360	14.626	18.9886
	0.004	0.004	0.010	0.006	0.012	0.199	0.221	0.630
	8.51	4.89	6.40	2.98	1.30	1.92	1.51	3.32
	101.6	88.6	103.2	102.0	94.4	103.6	97.5	94.9

[Table 2 on page 8]
	Target Concentration (ng/10 mg hair)							
	0.05	0.10	0.15	0.20	1.0	10	15	20
Nordiazepam
concentration	0.049
0.048
0.056
0.047
0.044	0.086
0.088
0.092
0.093
0.095	0.151
0.155
0.14
0.161
0.163	0.201
0.2
0.201
0.213
0.208	0.904
0.947
0.937
0.933
0.902	10.659
10.654
10.278
10.738
10.132	14.942
14.836
14.917
14.94
14.717	19.881
19.869
20.328
19.692
19.635
Average
S.D.
% CV
% of Target	0.0488	0.0908	0.154	0.2046	0.9246	10.492	14.870	19.881
	0.004	0.004	0.009	0.006	0.020	0.269	0.096	0.272
	9.10	4.08	5.95	2.78	2.20	2.57	0.65	1.37
	97.6	90.8	102.7	102.3	92.5	104.9	99.1	99.4
								
Oxazepam
concentration	0.058
0.05
0.049
0.048
0.055	0.101
0.093
0.099
0.091
0.093	0.168
0.168
0.161
0.158
0.162	0.21
0.211
0.198
0.2
0.198	0.926
0.93
0.903
0.905
0.878	9.841
10.277
10.146
10.394
10.417	15.053
14.791
14.561
15.271
15.164	19.451
19.701
19.889
19.595
19.593
Average
S.D.
% CV
% of Target	0.052	0.0954	0.1634	0.2034	0.9084	10.215	14.968	19.6458
	0.004	0.004	0.004	0.007	0.021	0.235	0.289	0.162
	8.27	4.54	2.72	3.22	2.30	2.30	1.93	0.83
	104.0	95.4	108.9	101.7	90.8	102.2	99.8	98.2

--- Page 9 ---
Temazepam 0.049 0.089 0.149 0.201 0.907 9.51 14.172 17.948
concentration 0.053 0.089 0.148 0.193 0.87 9.741 13.697 17.618
0.048 0.087 0.153 0.196 0.888 9.631 14.041 17.822
0.051 0.1 0.148 0.202 0.91 9.642 13.891 18.113
0.045 0.105 0.159 0.19 0.868 9.641 13.755 17.754
Average 0.0492 0.094 0.1514 0.1964 0.8886 9.633 13.911 17.851
S.D. 0.003 0.008 0.005 0.005 0.020 0.082 0.197 0.189
% CV 6.16 8.51 3.12 2.61 2.23 0.85 1.42 1.06
% of Target 98.4 94.0 100.9 98.2 88.9 96.3 92.7 89.3
A second study was conducted for precision using triplicate analyses of authentic (non-spiked)
benzodiazepine-positive samples. All six benzodiazepines measured with the confirmation
method were included in the study. Each replicate measurement was made from a separate hair
sample that was taken through the entire extraction process prior to analysis. Results for the six
benzodiazepines measured by the LC-MS/MS assay are summarized below.
Alprazolam (ng/10 mg hair)
Sample # 1 2 3 4 5
Replicate 1 6.477 0.199 2.941 7.408 3.802
Replicate 2 6.713 0.202 2.886 7.702 4.746
Replicate 3 5.711 0.243 3.159 7.269 4.189
Mean 6.3 0.2 3.0 7.5 4.2
Standard 0.5 0.0 0.1 0.2 0.5
Devation
%CV 8.3 11.5 4.8 3.0 11.2
Lorazepam (ng/10 mg hair)
Sample # 1 2 3 4
Replicate 1 1.174 0.555 0.536 0.341
Replicate 2 1.222 0.643 0.57 0.375
Replicate 3 1.102 0.591 0.59 0.333
Mean 1.2 0.6 0.6 0.3
Standard
0.1 0.0 0.0 0.0
Devation
%CV 5.2 7.4 4.8 6.4
9

[Table 1 on page 9]
Temazepam
concentration	0.049
0.053
0.048
0.051
0.045	0.089
0.089
0.087
0.1
0.105	0.149
0.148
0.153
0.148
0.159	0.201
0.193
0.196
0.202
0.19	0.907
0.87
0.888
0.91
0.868	9.51
9.741
9.631
9.642
9.641	14.172
13.697
14.041
13.891
13.755	17.948
17.618
17.822
18.113
17.754
Average
S.D.
% CV
% of Target	0.0492	0.094	0.1514	0.1964	0.8886	9.633	13.911	17.851
	0.003	0.008	0.005	0.005	0.020	0.082	0.197	0.189
	6.16	8.51	3.12	2.61	2.23	0.85	1.42	1.06
	98.4	94.0	100.9	98.2	88.9	96.3	92.7	89.3

[Table 2 on page 9]
Alprazolam (ng/10 mg hair)									
Sample #		1		2		3		4	5
Replicate 1		6.477		0.199		2.941		7.408	3.802
Replicate 2		6.713		0.202		2.886		7.702	4.746
Replicate 3		5.711		0.243		3.159		7.269	4.189
Mean		6.3		0.2		3.0		7.5	4.2
Standard
Devation		0.5		0.0		0.1		0.2	0.5
%CV		8.3		11.5		4.8		3.0	11.2
Lorazepam (ng/10 mg hair)									
Sample #	1		2		3		4		
Replicate 1	1.174		0.555		0.536		0.341		
Replicate 2	1.222		0.643		0.57		0.375		
Replicate 3	1.102		0.591		0.59		0.333		
Mean	1.2		0.6		0.6		0.3		
Standard
Devation	0.1		0.0		0.0		0.0		
%CV	5.2		7.4		4.8		6.4		

--- Page 10 ---
Diazepam (ng/10 mg hair)
Sample # 1 2 3 4 5
Replicate 1 0.229 8.365 1.417 4.642 0.77
Replicate 2 0.235 8.443 1.572 3.75 0.903
Replicate 3 0.205 8.519 1.215 3.929 0.818
Mean 0.2 8.4 1.4 4.1 0.8
Standard
0.0 0.1 0.2 0.5 0.1
Devation
%CV 7.1 0.9 12.8 11.5 8.1
Nordiazepam (ng/10 mg hair)
Sample # 1 2 3 4
Replicate 1 9.227 3.377 0.884 0.25
Replicate 2 9.928 3.725 0.923 0.226
Replicate 3 10.258 3.202 0.954 0.252
Mean 9.8 3.4 0.9 0.2
Standard
0.5 0.3 0.0 0.0
Devation
%CV 5.4 7.8 3.8 6.0
Oxazepam (ng/10 mg hair)
Sample # 1 2 3 4
Replicate 1 0.176 0.262 0.161 0.073
Replicate 2 0.179 0.267 0.149 0.071
Replicate 3 0.146 0.274 0.143 0.066
Mean 0.2 0.3 0.2 0.1
Standard
0.0 0.0 0.0 0.0
Devation
%CV 10.9 2.3 6.1 5.2
Temazepam (ng/10 mg hair)
Sample # 1 2 3 4 5
Replicate
1.342 0.22 0.141 0.133 0.136
1
Replicate
1.327 0.22 0.147 0.129 0.139
2
Replicate
1.291 0.233 0.114 0.136 0.132
3
Mean 1.3 0.2 0.1 0.1 0.1
Standard
0.0 0.0 0.0 0.0 0.0
Devation
%CV 2.0 3.3 13.1 2.6 2.6
10

[Table 1 on page 10]
Diazepam (ng/10 mg hair)					
Sample #	1	2	3	4	5
Replicate 1	0.229	8.365	1.417	4.642	0.77
Replicate 2	0.235	8.443	1.572	3.75	0.903
Replicate 3	0.205	8.519	1.215	3.929	0.818
Mean	0.2	8.4	1.4	4.1	0.8
Standard
Devation	0.0	0.1	0.2	0.5	0.1
%CV	7.1	0.9	12.8	11.5	8.1

[Table 2 on page 10]
Nordiazepam (ng/10 mg hair)				
Sample #	1	2	3	4
Replicate 1	9.227	3.377	0.884	0.25
Replicate 2	9.928	3.725	0.923	0.226
Replicate 3	10.258	3.202	0.954	0.252
Mean	9.8	3.4	0.9	0.2
Standard
Devation	0.5	0.3	0.0	0.0
%CV	5.4	7.8	3.8	6.0

[Table 3 on page 10]
Oxazepam (ng/10 mg hair)				
Sample #	1	2	3	4
Replicate 1	0.176	0.262	0.161	0.073
Replicate 2	0.179	0.267	0.149	0.071
Replicate 3	0.146	0.274	0.143	0.066
Mean	0.2	0.3	0.2	0.1
Standard
Devation	0.0	0.0	0.0	0.0
%CV	10.9	2.3	6.1	5.2

[Table 4 on page 10]
Temazepam (ng/10 mg hair)					
Sample #	1	2	3	4	5
Replicate
1	1.342	0.22	0.141	0.133	0.136
Replicate
2	1.327	0.22	0.147	0.129	0.139
Replicate
3	1.291	0.233	0.114	0.136	0.132
Mean	1.3	0.2	0.1	0.1	0.1
Standard
Devation	0.0	0.0	0.0	0.0	0.0
%CV	2.0	3.3	13.1	2.6	2.6

--- Page 11 ---
b. Linearity/assay reportable range:
The screening immunoassay is a qualitative test only; therefore, a linearity evaluation is not
applicable.
Linearity of the LC-MS/MS confirmation method
The linearity of the confirmation method was evaluated by spiking each of the
benzodiazepine analytes (Alprazolam, Lorazepam, Diazepam, Nordiazepam, Oxazepam,
and Temazepam) into a negative hair over the desired linear range of 0.05 to 20.0 ng/10 mg
hair. Eight concentrations within this range plus a zero concentration sample were
evaluated (0, 0.05, 0.1, 0.15, 0.2, 1.0, 10.0, 15.0, or 20.0 ng/10 mg hair). All levels for all
benzodiazepines demonstrated percent recoveries within +/- 10% of the expected value.
c. Traceability, Stability, Expected values (controls, calibrators, or methods):
Controls and calibrators are prepared as a methanolic solution containing oxazepam, and are
traceable to a commercial oxazepam source. The value of the cutoff for oxazepam is 1 ng/10
mg hair.
Stability studies for both controls and calibrators have been conducted. Protocols and
acceptance criteria were described and found to be acceptable. The manufacturer claims the
following expiration date for both controls and calibrators: When stored at less than or equal
to -10º C the calibrators and controls are stable for one year.
Shipping stability: 19 hair samples containing benzodiazepines were shipped overnight to
another location, held for four days, and then returned to Psychemedics by overnight
shipping. Samples were tested by the routine LC/MS/MS procedure both before being
shipped and after returning to Psychemedics. All six benzodiazepines were evaluated, and
recoveries after shipping were found to be acceptable.
Sample storage stability: 21 hair samples were stored in the same collection foil and card-
envelope provided with the hair collection kit, following the instructions provided in the
package insert. Samples were tested by LC/MS/MS on day 0, and again at 12 months,
following storage at 20o – 24o C (68o – 75o F). All six benzodiazepines were evaluated, and
recoveries after storage were found to be acceptable.
d. Detection limit:
The screening immunoassay is a qualitative test only; therefore, a detection limit evaluation
is not applicable. See section M.1.a. above for sensitivity around the immunoassay device
cutoff.
11

--- Page 12 ---
Detection Limit of the LC-MS/MS method
The sponsor performed a study to determine the Lower limit of Quantitation (LLOQ) of the
LC-MS/MS assay for each of the six benzodiazepines in the assay. Four types of hair
(Caucasian, Hispanic, African-American, and Asian) were obtained and were cut into three
segments for a total of 12 hair segments to be analyzed per drug. Each of the 12 hair
segments was independently spiked with each specific benzodiazepine and analyzed
according to the LC-MS/MS procedure stated in the package insert.
The results from the study support an LLOQ of 0.05 ng/10 mg hair, and a reportable range
of 0.05 to 20.0 ng/10 mg hair for all six drugs.
e. Analytical specificity:
Specificity of the immunoassay screening method
Immunoassay cross-reactivity with structurally related compounds
The cross-reactivity characteristics of the screening immunoassay was evaluated by spiking
various concentrations of benzodiazepines into drug-free hair samples and comparing the
result to the cutoff calibrator. The table below lists the percent cross-reactivity and the
approximate concentration of each compound required to produce a response approximately
equivalent to the cutoff concentration of the assay.
Expected
Percent Concentration in
Compound Cross- ng/10 mg hair
reactivity equivalent to
cutoff calibrator
Clobazam 550 0.18
Diazepam 550 0.18
Nimetazepam 550 0.18
Estazolam 400 0.25
Temazepam 312 0.32
Alprazolam 277 0.36
Flunitrazepam 222 0.45
Nordiazepam 220 0.45
Nitrazepam 220 0.45
N-Desmethylflunitrazepam 172 0.58
Lormetazepam 133 0.75
Oxazepam 100 1
Midazolam 42 2.4
12

[Table 1 on page 12]
Compound			Percent
Cross-
reactivity			Expected
Concentration in
ng/10 mg hair
equivalent to
cutoff calibrator		
	Clobazam			550			0.18	
	Diazepam			550			0.18	
	Nimetazepam			550			0.18	
	Estazolam			400			0.25	
	Temazepam			312			0.32	
	Alprazolam			277			0.36	
	Flunitrazepam			222			0.45	
	Nordiazepam			220			0.45	
	Nitrazepam			220			0.45	
	N-Desmethylflunitrazepam			172			0.58	
	Lormetazepam			133			0.75	
	Oxazepam			100			1	
	Midazolam			42			2.4	

[Table 2 on page 12]
Expected
Concentration in
ng/10 mg hair
equivalent to
cutoff calibrator

[Table 3 on page 12]
Percent
Cross-
reactivity

--- Page 13 ---
Expected
Percent Concentration in
Compound Cross- ng/10 mg hair
reactivity equivalent to
cutoff calibrator
Clonazepam 33 3
Triazolam 31 3.2
alpha-Hydroxyprazolam 22 4.5
Lorazepam 13 7.5
Bromazepam 8.3 12
Chlordiazepoxide 4 25
7-Aminoflunitrazepam 3.1 32
Hydroxymethylflurazepam 2 50
Alpha-Hydroxytriazolam 1.7 60
desalkylflurazepam 1 100
7-Aminonitrazepam 0.6 170
7-aminoclonazepam <0.3 >300
Flurazepam <0.3 >300
Prazepam <0.3 >300
Zolpidem Tartrate <0.3 >300
Interference from structurally unrelated compounds
The following potentially interfering compounds were tested using the screening
immunoassay on samples spiked with oxazepam at the cutoff and at ± 50% of the cutoff to
assess possible positive or negative interference. All potential interferents listed below
were tested at a concentration of 100 ng/10 mg hair. No positive or negative interference
was observed in this study.
11-nor-9-Carboxy-delta-9-THC Dextromethorphan Naproxen
1S, 2R Ephedrine Doxepin Nicotine
5-hydroxyindole-3-acetic acid Doxylamine succinate Normetanephrine (+/-)
8(-)-11-nor-9-Carboxy-delta-9
Ecgononine Nortriptyline
THC
Acetaminophen Erythromycin O-Desmethyvenlafaxine
Amitriptyline Ethosuximide Oxycodone
Amobarbital Ethylmorphine Penicillin G
Amoxicillin Fentanyl Pentazocine
Anhydroecgonine methyl ester Haloperidol Phendimetrazine
13

[Table 1 on page 13]
Compound			Percent
Cross-
reactivity			Expected
Concentration in
ng/10 mg hair
equivalent to
cutoff calibrator		
	Clonazepam			33			3	
	Triazolam			31			3.2	
	alpha-Hydroxyprazolam			22			4.5	
	Lorazepam			13			7.5	
	Bromazepam			8.3			12	
	Chlordiazepoxide			4			25	
7-Aminoflunitrazepam			3.1			32		
	Hydroxymethylflurazepam			2			50	
Alpha-Hydroxytriazolam			1.7			60		
	desalkylflurazepam			1			100	
	7-Aminonitrazepam			0.6			170	
	7-aminoclonazepam			<0.3			>300	
	Flurazepam			<0.3			>300	
	Prazepam			<0.3			>300	
	Zolpidem Tartrate			<0.3			>300	

[Table 2 on page 13]
Expected
Concentration in
ng/10 mg hair
equivalent to
cutoff calibrator

[Table 3 on page 13]
Percent
Cross-
reactivity

[Table 4 on page 13]
	11-nor-9-Carboxy-delta-9-THC			Dextromethorphan			Naproxen	
	1S, 2R Ephedrine			Doxepin			Nicotine	
	5-hydroxyindole-3-acetic acid			Doxylamine succinate			Normetanephrine (+/-)	
	8(-)-11-nor-9-Carboxy-delta-9		Ecgononine			Nortriptyline		
	THC							
	Acetaminophen			Erythromycin			O-Desmethyvenlafaxine	
	Amitriptyline			Ethosuximide			Oxycodone	
	Amobarbital			Ethylmorphine			Penicillin G	
	Amoxicillin			Fentanyl			Pentazocine	
	Anhydroecgonine methyl ester			Haloperidol			Phendimetrazine	

--- Page 14 ---
Atropine Hexobarbital Phendimetrazine bitartrate
Benzocaine Hydrocodone Phenmetrazine
Benzocaine Hydromorphone Phenobarbital
Buprenorphine Ibuprofen Procaine
Bupropion Imipramine Promethazine
Butabarbital Lidocaine Propanolol
Caffeine LSD Propoxyphene
Cannabinol Meperidine Protriptyline
Chlorpheniramine maleate Mepivacaine R-(-)Phenylephrine
Cis-tramadol HCl Metanephrine (+/-) R,R(-)-Pseudoephedrine
Codeine Methadone (+/-) Secobarbital
Cotinine Methanol Streptomycin
Synthetic cannabinoids CP 47,
Methaqualone Synthetic cannabinoid AM2201
497 (+/-)
Delta 8-THC Methyl phenidate Synthetic cannabinoid HU-211
Synthetic cannabinoids JWH-019,
Desipramine Morphine
081, 122, 200, and 250
Desmethyldoxepin Nalorphine Thioridazine
Despiramine Naloxone Trimipramine
Despropionyl fentanyl Naltrexone Vanilmandelic acid(+/-)
Venlafaxine hydochloride
Effect of cosmetic treatments
To evaluate any effects of cosmetic treatments, 20 hair samples negative for benzodiazepines and
8 hair samples positive for benzodiazepines were treated with the following cosmetic treatments:
permanent wave, relaxer, bleach, dye, and shampoo. After the treatments these samples and an
aliquot of the same hair samples, untreated, were digested and assayed by the immunoassay
screening method. All negative results remained negative and all positive results remained
positive after the treatments.
The effect of cosmetic treatments was also evaluated using the LC-MS/MS method, for the same
samples. The sponsor determined the concentrations of drug before and after treatment (%
recovery in parentheses) and the results are provided below (ND = not detected in either
untreated or treated samples).
14

[Table 1 on page 14]
	Atropine			Hexobarbital			Phendimetrazine bitartrate	
	Benzocaine			Hydrocodone			Phenmetrazine	
	Benzocaine			Hydromorphone			Phenobarbital	
	Buprenorphine			Ibuprofen			Procaine	
	Bupropion			Imipramine			Promethazine	
	Butabarbital			Lidocaine			Propanolol	
	Caffeine			LSD			Propoxyphene	
	Cannabinol			Meperidine			Protriptyline	
	Chlorpheniramine maleate			Mepivacaine			R-(-)Phenylephrine	
	Cis-tramadol HCl			Metanephrine (+/-)			R,R(-)-Pseudoephedrine	
	Codeine			Methadone (+/-)			Secobarbital	
	Cotinine			Methanol			Streptomycin	
	Synthetic cannabinoids CP 47,		Methaqualone			Synthetic cannabinoid AM2201		
	497 (+/-)							
	Delta 8-THC			Methyl phenidate			Synthetic cannabinoid HU-211	
Desipramine			Morphine				Synthetic cannabinoids JWH-019,	
							081, 122, 200, and 250	
	Desmethyldoxepin			Nalorphine			Thioridazine	
	Despiramine			Naloxone			Trimipramine	
	Despropionyl fentanyl			Naltrexone			Vanilmandelic acid(+/-)	
							Venlafaxine hydochloride	

--- Page 15 ---
Effect of Dye Product #2 on Benzodiazepines in Hair – ng/10 mg hair
Alprazolam Lorazepam Diazepam Nordiazepam Oxazepam Temazepam Sample
#
Untreated
ND 1.158 3.447 1.090 ND ND 1
1.563 0.792 ND ND ND ND 2
0.910 ND ND ND ND ND 3
0.992 ND ND ND ND ND 4
Dyed
2.075
ND 0.941 (81%) (60%) 1.195 (110%) ND ND 1
.901(58%) 0.740 (93%) ND ND ND ND 2
1.258(133%) ND ND ND ND ND 3
.623(63%) ND ND ND ND ND 4
Effect of Bleach Product #1 on Benzodiazepines in Hair – ng/10 mg hair
Alprazolam Lorazepam Diazepam Nordiazepam Oxazepam Temazepam Sample
#
Untreated
ND ND ND ND ND 0.847 1
ND ND ND 0.613 ND ND 2
0.403
1.737 ND 1.128 ND ND
(94%) 3
ND ND 3.826 5.057 ND ND
4
Bleached
0.996
ND ND ND ND ND (118%) 1
ND ND ND 0.476 (78%) ND ND 2
1.326
1.500 (86%) ND 0.378 (94%) (118%) ND ND 3
ND ND 2.930 (77%) 4.526 (89%) ND ND 4
15

[Table 1 on page 15]
Effect of Dye Product #2 on Benzodiazepines in Hair – ng/10 mg hair								
Alprazolam		Lorazepam	Diazepam	Nordiazepam	Oxazepam	Temazepam	Sample
#	
	Untreated							
ND		1.158	3.447	1.090	ND	ND	1	
1.563		0.792	ND	ND	ND	ND	2	
0.910		ND	ND	ND	ND	ND	3	
0.992		ND	ND	ND	ND	ND	4	
	Dyed							
ND		0.941 (81%)	2.075
(60%)	1.195 (110%)	ND	ND	1	
.901(58%)		0.740 (93%)	ND	ND	ND	ND	2	
1.258(133%)		ND	ND	ND	ND	ND	3	
.623(63%)		ND	ND	ND	ND	ND	4	

[Table 2 on page 15]
Effect of Bleach Product #1 on Benzodiazepines in Hair – ng/10 mg hair												
Alprazolam			Lorazepam	Diazepam	Nordiazepam		Oxazepam		Temazepam		Sample
#	
	Untreated											
ND			ND	ND	ND		ND		0.847		1	
ND			ND	ND	0.613		ND		ND		2	
1.737			ND	0.403
(94%)	1.128		ND		ND		3	
ND			ND	3.826	5.057		ND		ND		4	
Bleached												
ND		ND		ND	ND	ND		0.996
(118%)		1		
ND		ND		ND	0.476 (78%)	ND		ND		2		
1.500 (86%)		ND		0.378 (94%)	1.326
(118%)	ND		ND		3		
ND		ND		2.930 (77%)	4.526 (89%)	ND		ND		4		

--- Page 16 ---
Effect of Bleach Product #2 on Benzodiazepines in Hair –ng/10 mg hair
Sample
Alprazolam Lorazepam Diazepam Nordiazepam Oxazepam Temazepam
#
Untreated
ND ND 1.947 5.643 0.610 0.392
1
0.876 ND ND ND ND ND
2
1.410 0.567 ND ND ND ND
3
0.992 ND ND ND ND ND
4
Bleached
2.25 0.92
ND ND 5.941 (105%) 0.46 (118%)
(116%) (151%) 1
0.819 (93%) ND ND ND ND ND
2
1.330 (94%) 0.50 (88%) ND ND ND ND
3
.788 (79%) ND ND ND ND ND
4
Effect of Relaxer Product #1 on Benzodiazepines in Hair – ng/10 mg hair
Sample
Alprazolam Lorazepam Diazepam Nordiazepam Oxazepam Temazepam
#
Untreated
ND ND ND ND ND 0.847 1
ND ND ND 0.613 ND ND 2
ND ND 1.101 1.702 ND ND 3
0.226 1.158 3.447 1.070 ND ND 4
Treated
ND ND ND ND ND 0.985 (116%) 1
ND ND ND 0.641 (105%) ND ND 2
ND ND 1.11 (101%) 2.051 (121%) ND ND 3
0.314
1.37 (119%) 2.113 (61%) 0.970 (91%) ND ND 4
(139%)
16

[Table 1 on page 16]
Effect of Bleach Product #2 on Benzodiazepines in Hair –ng/10 mg hair									
Alprazolam		Lorazepam	Diazepam	Nordiazepam	Oxazepam	Temazepam		Sample
#	
	Untreated								
ND		ND	1.947	5.643	0.610		0.392	1	
0.876		ND	ND	ND	ND		ND	2	
1.410		0.567	ND	ND	ND		ND	3	
0.992		ND	ND	ND	ND		ND	4	
	Bleached								
ND		ND	2.25
(116%)	5.941 (105%)	0.92
(151%)	0.46 (118%)		1	
0.819 (93%)		ND	ND	ND	ND	ND		2	
1.330 (94%)		0.50 (88%)	ND	ND	ND	ND		3	
.788 (79%)		ND	ND	ND	ND	ND		4	

[Table 2 on page 16]
Effect of Relaxer Product #1 on Benzodiazepines in Hair – ng/10 mg hair								
Alprazolam		Lorazepam	Diazepam	Nordiazepam	Oxazepam	Temazepam	Sample
#	
	Untreated							
ND		ND	ND	ND	ND	0.847	1	
ND		ND	ND	0.613	ND	ND	2	
ND		ND	1.101	1.702	ND	ND	3	
0.226		1.158	3.447	1.070	ND	ND	4	
	Treated							
ND		ND	ND	ND	ND	0.985 (116%)	1	
ND		ND	ND	0.641 (105%)	ND	ND	2	
ND		ND	1.11 (101%)	2.051 (121%)	ND	ND	3	
0.314
(139%)		1.37 (119%)	2.113 (61%)	0.970 (91%)	ND	ND	4	

--- Page 17 ---
Effect of Relaxer Product #2 on Benzodiazepines in Hair – ng/10 mg hair
Alprazolam Lorazepam Diazepam Nordiazepam Oxazepam Temazepam Sample
#
Untreated
1.369 ND ND ND ND ND 1
5.957 ND .426 .210 ND .496 2
1.027 ND ND ND ND ND 3
ND ND 0.548 1.020 ND ND 4
Relaxed
1.228 (90%) ND ND ND ND ND 1
3.821 (64%) ND .392 (92%) .163 (78%) ND .319 (64%) 2
1.05 (103%) ND ND ND ND ND 3
ND ND 0.60 (109%) 1.172 (115%) ND ND 4
Effect of Shampoo Product #1 on Benzodiazepines in Hair - ng/10 mg hair
Sample
Alprazolam Lorazepam Diazepam Nordiazepam Oxazepam Temazepam
#
Untreated
ND ND ND ND ND 0.601
1
ND ND ND 6.928 ND ND
2
ND ND ND 0.281 ND ND
3
ND ND 1.947 5.643 0.610 0.392
4
Shampoo
ND ND ND ND ND 0.384 (64%)
1
ND ND ND 8.245 (119%) ND ND
2
ND ND ND 0.285 (101%) ND ND
3
2.258 0.77
ND ND 5.274 (93%) 0.50 (128%)
(116%) (127%) 4
17

[Table 1 on page 17]
Effect of Relaxer Product #2 on Benzodiazepines in Hair – ng/10 mg hair									
Alprazolam		Lorazepam		Diazepam	Nordiazepam	Oxazepam	Temazepam	Sample
#	
	Untreated								
1.369		ND	ND		ND	ND	ND	1	
5.957		ND	.426		.210	ND	.496	2	
1.027		ND	ND		ND	ND	ND	3	
ND		ND	0.548		1.020	ND	ND	4	
	Relaxed								
1.228 (90%)		ND	ND		ND	ND	ND	1	
3.821 (64%)		ND	.392 (92%)		.163 (78%)	ND	.319 (64%)	2	
1.05 (103%)		ND	ND		ND	ND	ND	3	
ND		ND	0.60 (109%)		1.172 (115%)	ND	ND	4	

[Table 2 on page 17]
Effect of Shampoo Product #1 on Benzodiazepines in Hair - ng/10 mg hair								
Alprazolam		Lorazepam	Diazepam	Nordiazepam	Oxazepam	Temazepam	Sample
#	
	Untreated							
ND		ND	ND	ND	ND	0.601	1	
ND		ND	ND	6.928	ND	ND	2	
ND		ND	ND	0.281	ND	ND	3	
ND		ND	1.947	5.643	0.610	0.392	4	
	Shampoo							
ND		ND	ND	ND	ND	0.384 (64%)	1	
ND		ND	ND	8.245 (119%)	ND	ND	2	
ND		ND	ND	0.285 (101%)	ND	ND	3	
ND		ND	2.258
(116%)	5.274 (93%)	0.77
(127%)	0.50 (128%)	4	

--- Page 18 ---
Effect of Shampoo Product #2 on Benzodiazepines in Hair - ng/10 mg hair
Alprazola Lorazepam Diazepa Nordiazepam Oxazepam Temazepam Sample
m m #
Untreated
1.563 0.792 ND ND ND ND 1
1.410 0.567 ND ND ND ND 2
0.992 ND ND ND ND ND 3
ND ND 0.766 1.824 ND ND 4
Shampoo
1.100
(70%) 0.605 (76%) ND ND ND ND 1
1.156
(82%) 0.57 (101%) ND ND ND ND 2
1.018
(103%) ND ND ND ND ND 3
0.613
ND ND (80%) 1.493 (82%) ND ND 4
Effect of Perm Product #1 on Benzodiazepines in Hair - ng/10 mg hair
Alprazolam Lorazepam Diazepam Nordiazepam Oxazepam Temazepam Sample
#
Untreated
ND ND ND ND ND 0.601 1
ND ND ND ND ND 0.847 2
ND ND 3.826 5.057 ND 0.120 3
1.800 ND 1.241 1.214 ND ND 4
Permed
ND ND ND ND ND 0.274 (46%) 1
ND ND ND ND ND 0.942 (111%) 2
2.016
ND ND (53%) 3.177 (63%) ND ND 3
2.119 1.000
(118%) ND (81%) 1.182(97%) ND ND 4
Effect of Perm Product #2 on Benzodiazepines in Hair - ng/10 mg hair
Alprazolam Lorazepam Diazepam Nordiazepam Oxazepam Temazepam Sample
#
Untreated
1.563 0.792 ND ND ND ND 1
2.634 ND ND ND ND ND 2
5.957 ND 0.426 ND ND 0.496 3
18

[Table 1 on page 18]
Effect of Shampoo Product #2 on Benzodiazepines in Hair - ng/10 mg hair								
Alprazola
m		Lorazepam	Diazepa
m	Nordiazepam	Oxazepam	Temazepam	Sample
#	
	Untreated							
1.563		0.792	ND	ND	ND	ND	1	
1.410		0.567	ND	ND	ND	ND	2	
0.992		ND	ND	ND	ND	ND	3	
ND		ND	0.766	1.824	ND	ND	4	
	Shampoo							
1.100
(70%)		0.605 (76%)	ND	ND	ND	ND	1	
1.156
(82%)		0.57 (101%)	ND	ND	ND	ND	2	
1.018
(103%)		ND	ND	ND	ND	ND	3	
ND		ND	0.613
(80%)	1.493 (82%)	ND	ND	4	

[Table 2 on page 18]
Effect of Perm Product #1 on Benzodiazepines in Hair - ng/10 mg hair									
Alprazolam		Lorazepam	Diazepam		Nordiazepam	Oxazepam	Temazepam	Sample
#	
	Untreated								
ND		ND	ND	ND		ND	0.601	1	
ND		ND	ND	ND		ND	0.847	2	
ND		ND	3.826	5.057		ND	0.120	3	
1.800		ND	1.241	1.214		ND	ND	4	
	Permed								
ND		ND	ND	ND		ND	0.274 (46%)	1	
ND		ND	ND	ND		ND	0.942 (111%)	2	
ND		ND	2.016
(53%)	3.177 (63%)		ND	ND	3	
2.119
(118%)		ND	1.000
(81%)	1.182(97%)		ND	ND	4	

[Table 3 on page 18]
Effect of Perm Product #2 on Benzodiazepines in Hair - ng/10 mg hair								
Alprazolam		Lorazepam	Diazepam	Nordiazepam	Oxazepam	Temazepam	Sample
#	
	Untreated							
1.563		0.792	ND	ND	ND	ND	1	
2.634		ND	ND	ND	ND	ND	2	
5.957		ND	0.426	ND	ND	0.496	3	

--- Page 19 ---
0.992 ND ND ND ND ND 4
Permed
1.138 0.575
(73%) (73%) ND ND ND ND 1
2.255
(86%) ND ND ND ND ND 2
3.014 0.247
(51%) ND (58%) ND ND 0.276 (56%) 3
0.913
(92%) ND ND ND ND ND 4
Specificity of the LC-MS/MS method
Cross-reactivity with structurally related compounds
The cross-reactivity characteristics of the LC-MS/MS confirmation assay were
evaluated by measuring hair samples spiked with benzodiazepines at the cutoff of
0.20 ng/10 mg/hair, and also containing the following structurally related compounds
at a concentration of 0.20 ng/10 mg/hair: Clonazepam, Estazolam, Flurazepam,
Meprobromate, Midazolam, Nitrazepam, Prazepam, Triazolam, and Zolpidem. All of
the samples spiked with the potential cross-reactant and one of the target drugs at the
cutoff produced a concentration within ± 15% of the spiked value of 0.20 ng/10
mg/hair. The sponsor concluded that these nine benzodiazepine compounds did not
cross-react or cause interference with the LC-MS/MS assay.
Interference from structurally unrelated compounds
The specificity of the LC-MS/MS confirmation assay with structurally unrelated
compounds was evaluated by measuring samples spiked with benzodiazepines at the
cutoff of 0.20 ng/10 mg/hair, containing the following compounds at the
concentrations listed: Cotinine (500 ng/10 mg hair), Nicotine (500 ng/10 mg hair),
Caffeine (500 ng/10 mg hair), Ibuprofen (50 ng/10 mg hair), Naproxen (50 ng/10 mg
hair), Phentermine (20 ng/10 mg hair), Pseudoephedrine (20 ng/10 mg hair),
Morphine (200 ng/10 mg hair), Hydrocodone (200 ng/10 mg hair), Oxycodone (200
ng/10 mg hair), Codeine (200 ng/10 mg hair), Cocaine (200 ng/10 mg hair),
Phencyclidine (200 ng/10 mg hair), Methamphetamine (200 ng/10 mg hair),
Amphetamine ((200 ng/10 mg hair), Methadone (200 ng/10 mg hair), Phenobarbital
(200 ng/10 mg hair), Phenytoin (200 ng/10 mg hair), Phenylephrine(200 ng/10 mg
hair) , Carbamazepine (200 ng/10 mg hair), Gabapentin (500 ng/10 mg hair),
Salicylic Acid (200 ng/10 mg hair), Valproic Acid (200 ng/10 mg hair),
Oxcarbazepine (200 ng/10 mg hair), Propoxyphene (200 ng/10 mg hair),
Acetaminophen (200 ng/10 mg hair), Norfloxacin (0.2 ng/10 mg hair), Psilocybin
(200 ng/10 mg hair), Nimesulide (200 ng/10 mg hair), Etifoxine (200 ng/10 mg hair) ,
Chlorcyclizine (200 ng/10 mg hair), and Teriflunomide (200 ng/10 mg hair).
19

[Table 1 on page 19]
0.992		ND		ND	ND	ND	ND	4	
	Permed								
1.138
(73%)		0.575
(73%)	ND		ND	ND	ND	1	
2.255
(86%)		ND	ND		ND	ND	ND	2	
3.014
(51%)		ND	0.247
(58%)		ND	ND	0.276 (56%)	3	
0.913
(92%)		ND	ND		ND	ND	ND	4	

--- Page 20 ---
All of the samples spiked with the potential interfering compounds and one of the
target drugs at the cutoff produced a concentration within ± 15% of the spiked value
of 0.20 ng/10 mg/hair. The sponsor concluded that the potentially interfering
compounds listed above did not cross-react or cause interference with the LC-MS/MS
assay.
Studies to evaluate environmental contamination
Studies were performed to evaluate environmental contamination. Two different
aliquots of 10 different hair specimens, previously shown to be negative for
benzodiazepines, were soaked in either a water-based solution containing 5 ng
benzodiazepines /mL or a saline-based solution containing 5 ng benzodiazepines /mL,
resulting in a range of benzodiazepines on the hair from below the Limit of
Quantitation (LOQ) to 0.452 ng of benzodiazepines /10 mg hair, prior to washing.
After washing hair samples according to the instructions in the product insert, no
samples contained an amount of drug above the LOQ of the confirmatory method.
f. Assay cut-off:
Analytical performance of the device around the claimed cutoff is described in
precision section M.1.a. above.
2. Comparison studies:
a. Method comparison with predicate device:
Accuracy of the immunoassay screening method
Method comparison studies were performed by comparing the results from 382 hair
samples on the immunoassay screening method to the confirmatory LC/MS/MS
method. The 382 samples included 318 head hair samples and 64 body hair samples.
The color of the hair samples included 159 black samples, 197 brown (from light
brown to dark brown), 8 blond, 4 red, and 14 gray. The ethnicities represented
included 175 Caucasian subjects, 40 African-American subjects, 125 Hispanic
subjects, and 41 Asian subjects.
20

--- Page 21 ---
Negative by
Near Cutoff Near Cutoff
the predicate High Positive
Negative Positive
device or less (greater than
(Between (Between the
than half the 50% above
50% below cutoff and
cutoff the cutoff
the cutoff and 50% above
concentration concentration)
Immunoassay the cutoff the cutoff
by
Screening concentration) concentration)
LC/MS/MS
Test Result
analysis
(>1.500 ng
(0.500 – 1.000 (1.001 – 1.500
(<0.500 ng oxazepam
ng oxazepam ng oxazepam
oxazepam equivalents/10
equivalents/10 equivalents/10
equivalents/10 mg hair)
mg hair) mg hair)
mg hair)
Positive 5* 19** 17 107
Negative 233 1 0 0
Discordant Results
Sum of
Immunoassay LC/MS/MS concentrations
Result Result based on cross-
reactivities
POS* 0.092 ng Alprazolam 0.255
POS* 0.093 ng Alprazolam 0.258
POS* 0.196 ng Nordiazepam 0.431
POS* 0.156 ng Alprazolam 0.432
POS* 0.111 ng Nordiazepam, 0.217
0.461
ng Oxazepam
POS** 0.191 ng Alprazolam 0.529
POS** 0.201 ng Alprazolam 0.557
POS** 0.493 ng Lorazepam 0.584
POS** 0.24 ng Alprazolam 0.665
POS** 0.121 ng Diazepam 0.666
POS** 0.073 ng Diazepam, 0.133 ng
0.694
Nordiazepam
POS** 0.266 ng Alprazolam 0.737
POS** 0.267 ng Alprazolam 0.74
POS** 0.267 ng Alprazolam 0.74
POS** 0.272 ng Alprazolam 0.753
POS** 0.347 ng Nordiazepam 0.763
POS** 0.283 ng Alprazolam 0.784
POS** 0.293 ng Nordiazepam, 0.158
0.803
ng Oxazepam
21

[Table 1 on page 21]
Immunoassay
Screening
Test Result				Negative by		Near Cutoff
Negative
(Between
50% below
the cutoff and
the cutoff
concentration)
(0.500 – 1.000
ng oxazepam
equivalents/10
mg hair)			Near Cutoff
Positive
(Between the
cutoff and
50% above
the cutoff
concentration)
(1.001 – 1.500
ng oxazepam
equivalents/10
mg hair)			High Positive
(greater than
50% above
the cutoff
concentration)
(>1.500 ng
oxazepam
equivalents/10
mg hair)		
				the predicate										
				device or less										
				than half the										
				cutoff										
				concentration										
				by										
				LC/MS/MS										
				analysis										
														
				(<0.500 ng										
				oxazepam										
				equivalents/10										
				mg hair)										
	Positive			5*			19**			17			107	
	Negative			233			1			0			0	

[Table 2 on page 21]
Near Cutoff
Negative
(Between
50% below
the cutoff and
the cutoff
concentration)


(0.500 – 1.000
ng oxazepam
equivalents/10
mg hair)

[Table 3 on page 21]
Near Cutoff
Positive
(Between the
cutoff and
50% above
the cutoff
concentration)


(1.001 – 1.500
ng oxazepam
equivalents/10
mg hair)

[Table 4 on page 21]
High Positive
(greater than
50% above
the cutoff
concentration)



(>1.500 ng
oxazepam
equivalents/10
mg hair)

[Table 5 on page 21]
Immunoassay
Screening
Test Result

[Table 6 on page 21]
						Sum of
concentrations
based on cross-
reactivities		
								
	Immunoassay			LC/MS/MS				
	Result			Result				
								
								
	POS*			0.092 ng Alprazolam			0.255	
	POS*			0.093 ng Alprazolam			0.258	
	POS*			0.196 ng Nordiazepam			0.431	
	POS*			0.156 ng Alprazolam			0.432	
POS*	POS*			0.111 ng Nordiazepam, 0.217		0.461		
				ng Oxazepam				
	POS**			0.191 ng Alprazolam			0.529	
	POS**			0.201 ng Alprazolam			0.557	
	POS**			0.493 ng Lorazepam			0.584	
	POS**			0.24 ng Alprazolam			0.665	
	POS**			0.121 ng Diazepam			0.666	
POS**	POS**			0.073 ng Diazepam, 0.133 ng		0.694		
				Nordiazepam				
	POS**			0.266 ng Alprazolam			0.737	
	POS**			0.267 ng Alprazolam			0.74	
	POS**			0.267 ng Alprazolam			0.74	
	POS**			0.272 ng Alprazolam			0.753	
	POS**			0.347 ng Nordiazepam			0.763	
	POS**			0.283 ng Alprazolam			0.784	
POS**	POS**			0.293 ng Nordiazepam, 0.158		0.803		
				ng Oxazepam				

[Table 7 on page 21]
Sum of
concentrations
based on cross-
reactivities

--- Page 22 ---
Sum of
Immunoassay LC/MS/MS concentrations
Result Result based on cross-
reactivities
POS** 0.099 ng Diazepam, 0.131 ng
0.833
Nordiazepam
POS** 0.069 ng Alprazolam, 0.303 ng
0.858
Nordiazepam
POS** 0.266 ng Alprazolam, 0.023 ng
0.863
Diazepam
POS** 0.322 ng Alprazolam 0.892
POS** 0.427 ng Nordiazepam 0.939
POS** 0.308 ng Temazepam 0.961
The accuracy of the LC-MS/MS method is supported by the data collected to evaluate
intra-assay precision around the cutoff (see section M.1.a.). The average recovery for
all concentrations for all six benzodiazepines was within ± 7% of the target value.
Recovery study:
The sponsor conducted a study to evaluate recovery for all six benzodiazepines at
concentrations of 0.2, 10, and 20 ng/10 mg hair. For each combination of drug and
concentration level, nine individual hair samples were prepared and analyzed.
Results are summarized below.
Alprazolam Lorazepam Diazepam
Sample ng/10 mg % of ng/10 mg % of ng/10 mg % of
# hair target hair target hair target
1 0.171 85.5 0.172 86 0.171 85.5
2 0.180 90.0 0.206 103 0.215 107.5
3 0.179 89.5 0.202 101 0.203 101.5
4 0.183 91.5 0.192 96 0.182 91.0
5 0.187 93.5 0.181 90.5 0.190 95.0
6 0.172 86.0 0.179 89.5 0.196 98.0
7 0.179 89.5 0.213 106.5 0.172 86.0
8 0.199 99.5 0.177 88.5 0.190 95.0
9 0.189 94.5 0.209 104.5 0.211 105.5
Average 0.182 91.1 0.192 96.2 0.192 96.1
S.D. 0.009 4.35 0.016 7.79 0.016 7.86
%CV 4.78 4.78 8.10 8.10 8.18 8.18
22

[Table 1 on page 22]
						Sum of
concentrations
based on cross-
reactivities		
								
	Immunoassay			LC/MS/MS				
	Result			Result				
								
								
POS**	POS**			0.099 ng Diazepam, 0.131 ng		0.833		
				Nordiazepam				
POS**				0.069 ng Alprazolam, 0.303 ng		0.858		
				Nordiazepam				
POS**				0.266 ng Alprazolam, 0.023 ng		0.863		
				Diazepam				
	POS**			0.322 ng Alprazolam			0.892	
	POS**			0.427 ng Nordiazepam			0.939	
	POS**			0.308 ng Temazepam			0.961	

[Table 2 on page 22]
Sum of
concentrations
based on cross-
reactivities

[Table 3 on page 22]
Sample
#	Alprazolam
ng/10 mg % of
hair target		Lorazepam
ng/10 mg % of
hair target		Diazepam
ng/10 mg % of
hair target	
1	0.171	85.5	0.172	86	0.171	85.5
2	0.180	90.0	0.206	103	0.215	107.5
3	0.179	89.5	0.202	101	0.203	101.5
4	0.183	91.5	0.192	96	0.182	91.0
5	0.187	93.5	0.181	90.5	0.190	95.0
6	0.172	86.0	0.179	89.5	0.196	98.0
7	0.179	89.5	0.213	106.5	0.172	86.0
8	0.199	99.5	0.177	88.5	0.190	95.0
9	0.189	94.5	0.209	104.5	0.211	105.5
						
Average	0.182	91.1	0.192	96.2	0.192	96.1
S.D.	0.009	4.35	0.016	7.79	0.016	7.86
%CV	4.78 4.78		8.10 8.10		8.18 8.18	

--- Page 23 ---
Sample
# Nordiazepam Oxazepam Temazepam
% of ng/10 mg % of ng/10 mg % of
ng/10 mg hair target hair target hair target
1 0.198 99 0.179 89.5 0.172 86.0
2 0.207 103.5 0.227 113.5 0.185 92.5
3 0.229 114.5 0.22 110.0 0.183 91.5
4 0.193 96.5 0.216 108.0 0.186 93.0
5 0.192 96 0.186 93.0 0.183 91.5
6 0.177 88.5 0.2 100.0 0.172 86.0
7 0.196 98 0.228 114.0 0.172 86.0
8 0.214 107 0.225 112.5 0.173 86.0
9 0.172 86 0.221 110.5 0.184 92.0
Average 0.198 98.8 0.211 105.7 0.179 89.4
S.D. 0.018 8.80 0.018 9.21 0.006 3.25
%CV 8.91 8.91 8.72 8.72 3.56 3.63
Alprazolam Lorazepam Diazepam
Sample ng/10 mg % of ng/10 mg % of ng/10 mg % of
# hair target hair target hair target
10 9.19 91.9 9.67 96.7 10.35 103.4
11 8.91 89.1 8.68 86.8 9.11 91.1
12 9.02 90.2 8.82 88.2 10.17 101.7
13 8.92 89.2 9.50 95.0 9.14 91.4
14 8.93 89.3 9.83 98.3 9.72 97.2
15 10.51 105.1 8.68 86.8 9.23 92.3
16 9.30 93.0 8.87 88.7 10.00 100.0
17 9.84 98.4 8.75 87.5 9.79 97.9
18 9.25 92.5 9.40 94.0 9.41 94.1
Average 9.320 93.2 9.133 91.3 9.657 96.6
S.D. 0.535 5.34 0.463 4.63 0.459 4.58
%CV 5.74 5.73 5.07 5.07 4.75 4.74
23

[Table 1 on page 23]
Sample
#	Nordiazepam
% of
ng/10 mg hair target		Oxazepam
ng/10 mg % of
hair target		Temazepam
ng/10 mg % of
hair target	
1	0.198	99	0.179	89.5	0.172	86.0
2	0.207	103.5	0.227	113.5	0.185	92.5
3	0.229	114.5	0.22	110.0	0.183	91.5
4	0.193	96.5	0.216	108.0	0.186	93.0
5	0.192	96	0.186	93.0	0.183	91.5
6	0.177	88.5	0.2	100.0	0.172	86.0
7	0.196	98	0.228	114.0	0.172	86.0
8	0.214	107	0.225	112.5	0.173	86.0
9	0.172	86	0.221	110.5	0.184	92.0
						
Average	0.198	98.8	0.211	105.7	0.179	89.4
S.D.	0.018	8.80	0.018	9.21	0.006	3.25
%CV	8.91	8.91	8.72	8.72	3.56	3.63

[Table 2 on page 23]
Sample
#	Alprazolam
ng/10 mg % of
hair target		Lorazepam
ng/10 mg % of
hair target		Diazepam
ng/10 mg % of
hair target	
10	9.19	91.9	9.67	96.7	10.35	103.4
11	8.91	89.1	8.68	86.8	9.11	91.1
12	9.02	90.2	8.82	88.2	10.17	101.7
13	8.92	89.2	9.50	95.0	9.14	91.4
14	8.93	89.3	9.83	98.3	9.72	97.2
15	10.51	105.1	8.68	86.8	9.23	92.3
16	9.30	93.0	8.87	88.7	10.00	100.0
17	9.84	98.4	8.75	87.5	9.79	97.9
18	9.25	92.5	9.40	94.0	9.41	94.1
						
Average	9.320	93.2	9.133	91.3	9.657	96.6
S.D.	0.535	5.34	0.463	4.63	0.459	4.58
%CV	5.74	5.73	5.07	5.07	4.75	4.74

--- Page 24 ---
Sample
# Nordiazepam Oxazepam Temazepam
% of ng/10 mg % of ng/10 mg % of
ng/10 mg hair target hair target hair target
10 10.79 107.87 10.92 109.2 9.47 94.7
11 9.91 99.13 10.10 101.0 8.54 85.4
12 9.56 95.6 10.66 106.6 8.52 85.2
13 9.68 96.8 10.34 103.4 9.05 90.5
14 9.15 91.52 9.60 96.0 8.62 86.2
15 9.47 94.7 10.27 102.7 9.34 93.4
16 10.20 101.97 10.42 104.2 9.04 90.4
17 9.57 95.72 10.21 102.1 8.63 86.3
18 9.89 98.94 8.52 85.2 8.95 89.5
Average 9.803 98.0 10.115 101.1 8.905 89.1
S.D. 0.475 4.75 0.702 7.02 0.351 3.51
%CV 4.85 4.85 6.94 6.94 3.94 3.94
Alprazolam Lorazepam Diazepam
Sample ng/10 mg % of ng/10 mg % of ng/10 mg % of
# hair target hair target hair target
19 20.07 100.3 18.58 92.9 17.45 87.2
20 20.87 104.4 20.48 102.4 17.39 87.0
21 19.39 97.0 19.63 98.1 17.97 89.8
22 19.57 97.8 18.51 92.6 17.31 86.6
23 20.11 100.5 19.83 99.1 18.19 90.9
24 19.93 99.7 19.26 96.3 18.81 94.1
25 20.93 104.7 19.40 97.0 18.00 90.0
26 19.57 97.9 20.40 102.0 17.69 88.4
27 21.02 105.1 19.63 98.1 17.18 85.9
Average 20.16 100.8 19.52 97.6 17.78 88.9
S.D. 0.631 3.16 0.689 3.44 0.520 2.60
%CV 3.13 3.13 3.53 3.53 2.92 2.92
24

[Table 1 on page 24]
Sample
#	Nordiazepam
% of
ng/10 mg hair target		Oxazepam
ng/10 mg % of
hair target		Temazepam
ng/10 mg % of
hair target	
10	10.79	107.87	10.92	109.2	9.47	94.7
11	9.91	99.13	10.10	101.0	8.54	85.4
12	9.56	95.6	10.66	106.6	8.52	85.2
13	9.68	96.8	10.34	103.4	9.05	90.5
14	9.15	91.52	9.60	96.0	8.62	86.2
15	9.47	94.7	10.27	102.7	9.34	93.4
16	10.20	101.97	10.42	104.2	9.04	90.4
17	9.57	95.72	10.21	102.1	8.63	86.3
18	9.89	98.94	8.52	85.2	8.95	89.5
						
Average	9.803	98.0	10.115	101.1	8.905	89.1
S.D.	0.475	4.75	0.702	7.02	0.351	3.51
%CV	4.85	4.85	6.94	6.94	3.94	3.94

[Table 2 on page 24]
Sample
#	Alprazolam
ng/10 mg % of
hair target		Lorazepam
ng/10 mg % of
hair target		Diazepam
ng/10 mg % of
hair target	
19	20.07	100.3	18.58	92.9	17.45	87.2
20	20.87	104.4	20.48	102.4	17.39	87.0
21	19.39	97.0	19.63	98.1	17.97	89.8
22	19.57	97.8	18.51	92.6	17.31	86.6
23	20.11	100.5	19.83	99.1	18.19	90.9
24	19.93	99.7	19.26	96.3	18.81	94.1
25	20.93	104.7	19.40	97.0	18.00	90.0
26	19.57	97.9	20.40	102.0	17.69	88.4
27	21.02	105.1	19.63	98.1	17.18	85.9
						
Average	20.16	100.8	19.52	97.6	17.78	88.9
S.D.	0.631	3.16	0.689	3.44	0.520	2.60
%CV	3.13	3.13	3.53	3.53	2.92	2.92

--- Page 25 ---
Sample
# Nordiazepam Oxazepam Temazepam
% of ng/10 mg % of ng/10 mg % of
ng/10 mg hair target hair target hair target
19 19.54 97.7 21.63 108.2 19.78 98.9
20 18.23 91.1 19.48 97.4 19.49 97.5
21 19.50 97.5 19.57 97.9 21.13 105.7
22 19.65 98.2 20.43 102.1 19.05 95.2
23 19.11 95.6 20.24 101.2 20.58 102.9
24 18.67 93.4 19.63 98.2 19.57 97.9
25 19.98 99.9 20.98 104.9 20.28 101.4
26 19.40 97.0 18.78 93.9 19.57 97.8
27 18.37 91.8 19.87 99.4 18.77 93.9
Average 19.16 95.8 20.07 100.3 19.80 99.0
S.D. 0.610 3.05 0.860 4.30 0.745 3.72
%CV 3.18 3.18 4.29 4.29 3.76 3.76
b. Matrix comparison:
Not applicable. The assay is intended for only one sample matrix.
3. Clinical studies:
a. Clinical Sensitivity:
Not applicable.
b. Clinical specificity:
Not applicable.
c. Other clinical supportive data (when a. and b. are not applicable):
Not applicable.
4. Clinical cut-off:
Not applicable.
5. Expected values/Reference range:
Not applicable.
25

[Table 1 on page 25]
Sample
#	Nordiazepam
% of
ng/10 mg hair target		Oxazepam
ng/10 mg % of
hair target		Temazepam
ng/10 mg % of
hair target	
19	19.54	97.7	21.63	108.2	19.78	98.9
20	18.23	91.1	19.48	97.4	19.49	97.5
21	19.50	97.5	19.57	97.9	21.13	105.7
22	19.65	98.2	20.43	102.1	19.05	95.2
23	19.11	95.6	20.24	101.2	20.58	102.9
24	18.67	93.4	19.63	98.2	19.57	97.9
25	19.98	99.9	20.98	104.9	20.28	101.4
26	19.40	97.0	18.78	93.9	19.57	97.8
27	18.37	91.8	19.87	99.4	18.77	93.9
						
Average	19.16	95.8	20.07	100.3	19.80	99.0
S.D.	0.610	3.05	0.860	4.30	0.745	3.72
%CV	3.18	3.18	4.29	4.29	3.76	3.76

--- Page 26 ---
N. Proposed Labeling:
The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.
O. Conclusion:
The submitted information in this premarket notification is complete and supports a
substantial equivalence decision.
26